HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics (NASDAQ:HALO) : vimarsana.com

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 27.23% from the company’s […]

Related Keywords

Japan , United States , Belgium , Switzerland , Michaelj Labarre , , Hsbc Holdings , Allspring Global Investments Holdings , Halozyme Therapeutics Inc , International Assets Investment Management , Goldman Sachs Group , Harvey Capital Management Inc , Halozyme Therapeutics , Get Free Report , Assets Investment Management , Capital Management , Global Investments Holdings , Aurora Investment Counsel , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Reiterated Rating , Hc Wainwright ,